GH Research : Corporate Presentation

GH Research

Corporate Presentation

GH Research PLC (NASDAQ: GHRS)

May 2022

2022© GH Research PLC	1

Disclaimer Regarding Forward-Looking Statements

This presentation has been prepared by GH Research PLC ("GH Research") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or adviser of GH Research. This presentation does not purport to be all-inclusive or to contain all of the information you may desire.

This presentation does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "could', "expect", "should", "plan", "intend", "estimate", "will", "potential" and "ongoing", among others, although not all forward-looking statements contain these identifying words.

Any statements contained herein that do not describe historical facts are forward-looking statements that are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with GH Research's research and development efforts; the inherent uncertainties associated with the conduct, timing and results of nonclinical and clinical studies of GH Research's product candidates; GH Research's ability to obtain, maintain, enforce and defend issued patents; the adequacy of GH Research's capital resources, the availability of additional funding and GH Research's cash runway; and other factors, risks and uncertainties described in GH Research's filings with the U.S. Securities and Exchange Commission.

Except as otherwise noted, these forward-looking statements speak only as of the date of this presentation, and GH Research undertakes no obligation to update or revise any of such statements to reflect events or circumstances occurring after this presentation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond GH Research's control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in any such forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. GH Research cautions you not to place undue reliance on the forward-looking statements contained in this presentation.

2022© GH Research PLC	2

Seeking

Ultra-Rapid, Durable Remissions

in Depression

2022© GH Research PLC	3

Pipeline

Stage of Development

PROGRAMS	INDICATION	PRECLINICAL	PHASE 1	PHASE 2a	PHASE 2b	PHASE 3	Next Stage
	Treatment-Resistant						Initiate Phase 2b trial
						in TRD
	Depression (TRD)
						(GH001-TRD-201)
GH001
5-MeO-DMT for inhalation							Initiate Phase 2a trial
administration	Bipolar II Disorder (BDII)*						in BDII
							(GH001-BD-202)
	Postpartum Depression						Initiate Phase 2a trial
						in PPD
	(PPD)*
						(GH001-PPD-203)
GH002 / GH003	Psychiatric or Neurological						Complete preclinical
5-MeO-DMT for injection /
Disorder						development
intranasal administration
	Complete

*In light of our completed Phase 1 clinical trials of GH001 in healthy volunteers and our completed Phase 1/2 trial in TRD, we recently submitted clinical trial applications to begin two Phase 2a trials in patients with BDII and a current major depressive episode and in patients with PPD, respectively. We believe that we can proceed to Phase 2a trials for these two indications based on existing preclinical and clinical data for GH001.

2022© GH Research PLC	4

The Problem for Patients with Depression

Established Therapies are Slow-Acting

(STAR*D study, Remission Rate Over Time, Treatment Step 1 = Citalopram)

... Remission Rates in TRD < 15%

(STAR*D study, Remission Rates Treatment Steps 1 to 4)

Cumulative Remission Rate (% Patients)

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

0

Average time to remission is ~6 weeks

2

4

6

8

10

12

14

	100%		~33% no remission				100%
	90%					90%	(line)
	despite 4 treatment steps
(%) (bar)	80%				80%
							Rate (%)
70%								70%
60%					67%		60%
Remission Rates			62%			Cumulative Remission
50%							50%
	56%
40%	37%	31%						40%
30%							30%
20%			14%		13%	20%
10%								10%
	0%	1	2	3		4		0%

Week

Adapted from Trivedi et al., Am J Psychiatry 2006 and Rush et al., Am J Psychiatry 2006

Treatment Step

2 or more prior therapies = TRD

2022© GH Research PLC	5